PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-12 pm EDT
50.11 USD   +3.77%
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US grapples with whether to modify COVID vaccine for fall

06/27/2022 | 11:00am EDT

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match recent changes of the shape-shifting coronavirus.

Moderna and Pfizer have tested updated shots against the super-contagious omicron variant, and advisers to the Food and Drug Administration will debate Tuesday if it’s time to make a switch — setting the stage for similar moves by other countries.

“This is science at its toughest,” FDA vaccine chief Dr. Peter Marks told The Associated Press, adding that a final decision is expected within days of the advisory panel's recommendation.

Current COVID-19 vaccines saved millions of lives around the world in just their first year of use. And the Moderna and Pfizer shots still offer strong protection against the worst outcomes -- severe illness and death — especially after a booster dose.

But those vaccines target the original coronavirus strain and between waning immunity and a relentless barrage of variants, protection against infections has dropped markedly. The challenge is deciding if tweaked boosters offer a good chance of blunting another surge when there's no way to predict which mutant will be the main threat.

In an analysis prepared for Tuesday's meeting, FDA officials acknowledged targeting last winter's version of omicron is “somewhat outdated" since it already has been replaced by its even more contagious relatives.

“We would obviously like to get it right enough," Marks said, so that with one more shot “we get a full season of protection.”

Many experts say updated boosters promise at least a little more benefit.

“It is more likely to be helpful” than simply giving additional doses of today’s vaccine, said epidemiologist William Hanage of the Harvard T.H. Chan School of Public Health.

That’s assuming the virus doesn’t throw another curve ball.

“We’re following rather than getting ahead which is so vexing -- that we haven’t come up with a better variant-proof vaccine,” said Dr. Eric Topol, head of the Scripps Research Translational Institute, who has urged a major government push for next-generation immunizations.

Adding to concern about a winter COVID-19 wave is that about half of Americans eligible for that all-important first booster dose never got it. An updated version might entice some of them.

But “we do need to change our expectations,” said Dr. William Moss of the Johns Hopkins Bloomberg School of Public Health, who noted that studies early in the pandemic raised unrealistic hopes of blocking even the mildest infections. “Our strategy can’t be booster doses every couple of months, even every six months, to prevent infections.”

The top candidates are what scientists call “bivalent” shots — a combination of the original vaccine plus omicron protection.

That’s because the original vaccines do spur production of at least some virus-fighting antibodies strong enough to cross-react with newer mutants -- in addition to their proven benefits against severe disease, said University of Pennsylvania immunologist E. John Wherry.

“Being able to push the boost response a little bit in one direction or the other without losing the core is really important,” he said.

Moderna and Pfizer found their combo shots substantially boosted levels of omicron-fighting antibodies in adults who'd already had three vaccinations, more than simply giving another regular dose.

Recipients also developed antibodies that could fight omicron’s newest relatives named BA.4 and BA.5, although not nearly as many. It's not clear how much protection that will translate into, and for how long.

Antibodies are a key first layer of defense that form after vaccination or a prior infection. They can prevent infection by recognizing the outer coating of the coronavirus -- the spike protein -- and blocking it from entering your cells.

But antibodies naturally wane and each new variant comes with a different-looking spike protein, giving it a better chance of evading detection by remaining antibodies. Separate studies published this month in Nature and the New England Journal of Medicine show the newest omicron relatives are even better at dodging antibodies — both in the vaccinated and in people who recovered from the original omicron.

That first booster people were supposed to get strengthened immune memory, helping explain why protection against hospitalization and death is proving more durable. If the virus sneaks past antibodies, different defenders called T cells spring into action, attacking infected cells to curb illness.

“T cells recognize the virus in a fundamentally different way,” not hunting for disguised spike protein but for parts of the virus that so far haven't been altered as much, said Penn’s Wherry.

Still, as people get older, all parts of their immune system gradually weaken. There’s little data on how long T cell protection against COVID-19 lasts or how it varies with different mutations or vaccines.

Wherry and dozens of other scientists recently petitioned the FDA to quit focusing solely on antibodies and start measuring T cells as it decides vaccination strategy.

The Biden administration has made clear that it needs Congress to provide more money so that if the FDA clears updated boosters, the government can buy enough for every American who wants one. And Dr. Anthony Fauci, the government's top infectious disease expert, told Congress last week more research funding also is critical to create better next-generation vaccines, such as nasal versions that might better block infection in the nose or more variant-proof shots.

“The virus is changing and we need to keep up with it,” Fauci, said.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -0.37% 171.18 Delayed Quote.-32.60%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
All news about PFIZER, INC.
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/12Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational..
AQ
08/12There are two ways to see inflation data
MS
08/12Pfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
08/12Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
08/12Pfizer Inc. Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumoc..
CI
08/12GSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
08/12Haleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,89x
Yield 2022 3,23%
Capitalization 281 B 281 B -
EV / Sales 2022 2,65x
EV / Sales 2023 3,37x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 50,11 $
Average target price 56,53 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.14%281 235
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550